Safety and efficacy of tegoprazan in patients treated with dual antiplatelet therapy after coronary stenting for acute myocardial infarction Authors: Oh-Hyun Lee, Seok-Jae Heo, Seong Huan Choi, Ji Woong Roh, Eui Im, Deok-Kyu Cho, Yongcheol Kim Published: 2026 ABSTRACT AbstractThis study compared the efficacy and safety of tegoprazan versus proton-pump inhibitors (PPIs) for gastrointestinal (GI) protection in patients receiving dual antiplatelet therapy (DAPT) after undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Using a Korean Nationwide database (March 2019 to September 2022), 21,276 patients treated with tegoprazan (n = 2,075) or PPIs (n = 19,201) in combination with DAPT after PCI for AMI were analyzed. The primary efficacy endpoint was GI bleeding at 1 year, and the primary safety endpoint was major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of myocardial infarction or stroke. In the crude cohort, tegoprazan was associated with a lower risk of GI bleeding and major bleeding with similar MACCEs rates at 1 year compared to PPIs. After propensity-score matching, tegoprazan was consistently associated with lower risks of GI bleeding (hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.54–0.98, P = 0.04) and major bleeding (HR 0.69, 95% CI 0.49–0.98, P = 0.04), without increasing the risk of MACCEs (HR 0.86, 95% CI 0.59–1.26, P = 0.45) at 1 year. In patients with AMI treated with DAPT, tegoprazan was associated with a significantly lower GI bleeding risk versus PPIs, without increasing ischemic events.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-64142-2.Subject terms: Cardiology, Diseases, Gastroenterology, Medical research Introduction Dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitors is essential after coronary stenting to reduce ischemic events, including stent thrombosis1,2. Current guidelines recommend maintaining DAPT for at least 6–12 months in patients with ischemic heart disease (IHD) who have undergone percutaneous coronary intervention (PCI)3,4. Moreover, potent P2Y12 inhibitors, including ticagrelor and prasugrel, have been shown to decrease the incidence of stent thrombosis, reducing the ischemic risk in the setting of acute coronary syndrome5,6. However, bleeding risk remains a major concern in patients with IHD because DAPT significantly increases the risk of gastrointestinal (GI) bleeding. GI bleeding after PCI is associated with increased morbidity, mortality, prolonged hospital stay, and higher healthcare costs7. Conventional GI protection with proton pump inhibitors (PPIs) has been reported to be beneficial in preventing GI bleeding in patients treated with DAPT after PCI8–10. However, drug–drug interactions between P2Y12 inhibitors and PPIs, especially in the East Asian population, have not been fully addressed. The East Asian population exhibits a unique genetic trait, specifically a higher frequency of the CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) loss-of-function allele than that in the Caucasian population11. Furthermore, Asian patients treated with antiplatelet therapy have a tendency toward a lower ischemic risk and higher bleeding risk than the Western population, as reported in studies on the bleeding outcomes of patients treated with DAPT after PCI12. Recently, GI protection using tegoprazan, a potassium-competitive acid blocker (P-CAB), has emerged as an option that can potentially mitigate the limitations of PPIs in the treatment of gastric ulcers and bleeding13–15. Theoretically, the longer half-life, rapid onset time, and reduced interaction of tegoprazan with CYP2C19 should lead to better therapeutic performance compared to PPIs16,17. However, data comparing the effectiveness of tegoprazan and PPIs in patients treated with DAPT are lacking. Therefore, this study aimed to evaluate the safety and efficacy of tegoprazan compared to PPIs in patients treated with DAPT after PCI with stenting, using a Korean nationwide cohort database. Methods Data source This study used clinical data from a nationwide Korean medical claims database. South Korea’s healthcare system covers approximately 98% of the population, and claims data of the Health Insurance Review and Assessment Service (HIRA) contain 90% of the patients’ healthcare claims information18. The HIRA claims data comprise prescription records, including medication, number of days supplied, number of pills, and dosage. Medical claims encompass diagnostic and procedural information coded according to the International Classification of Diseases, 10th Revision (ICD-10) for inpatient admissions and outpatient clinic visits. From this database, we collected information on demographics, clinical covariates, diagnostic and procedural information, study drugs, and concomitant cardioactive medications. Further details are provided in Table S1. The extracted data were converted into an editable format so that the researchers could organize the relevant medical information into a standardized dataset. This conversion enabled adequate configuration of data into tables such as the baseline clinical parameters and study endpoints. This study was approved by the Institutional Review Board (IRB) of Yongin Severance Hospital (IRB approval no. 9-2022-0177) and the HIRA Data Access Committee (approval no. M20230329002). This study was conducted in accordance with the principles of the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study and anonymized nature of the health insurance claims database. Definition of diagnosis and covariate Acute myocardial infarction (AMI) was defined as hospitalization with a primary diagnosis of AMI, identified by the ICD-10 codes I21-I23. Coronary stent implantation was identified using the HIRA procedure codes M6551, M6552, M6561, M6562, M6563, M6564, M6571, and M6572. The HIRA claims database contains comprehensive information, such as clinical diagnoses; health insurance claims; concomitant medication prescription records, including the number of prescription days; and hospital visit records, including the visit type and duration of hospitalization. Baseline demographic information, such as age and sex, as well as prior history of cardiovascular (CV) comorbidities and GI procedures, was also available in the database. Study design and population From the HIRA database, we identified patients diagnosed with AMI between March 2019 and September 2022. Patients who underwent PCI with stent implantation and were prescribed either PPIs or tegoprazan for over 30 days were eligible for our study. Exclusion criteria were age below 19 years; antiplatelet medication prescription for less than 30 days; receipt of thrombolytic therapy; prescription of anticoagulants (non-vitamin K antagonist oral anticoagulant and warfarin); treatment with histamine H2 receptor antagonists; no treatment with either PPIs or tegoprazan; prescription of either tegoprazan or PPI for less than 30 days; or concomitant use of both PPIs and tegoprazan (Fig. 1). The selected study population was divided into tegoprazan and PPIs groups. Due to the large size discrepancy between the two groups, sequential propensity score (PS) matching was conducted to minimize bias. Study flowchart. Abbreviations: PCI, percutaneous coronary intervention; NOAC, non-vitamin K antagonist oral anticoagulant; PPI, proton pump inhibitor Endpoints The co-primary efficacy endpoint was the risk of GI bleeding at 1 year. The co-primary safety endpoint was the occurrence of major adverse cardiac and cerebrovascular events (MACCE) at 1 year, defined as a composite of myocardial infarction (MI) or stroke. The secondary endpoints were MI, stroke, major bleeding, and intracranial hemorrhage (ICH). Major bleeding was defined as a fatal bleeding event, bleeding requiring hospitalization, or bleeding occurring at critical sites (intracranial, intraspinal, intraarticular, intraocular, pericardial, retroperitoneal, or intramuscular with compartment syndrome). High GI bleeding risk was defined as a medical history of any of the following: (1) GI bleeding or peptic ulcer; (2) Helicobacter pylori infection; (3) age > 65 years; or (4) concomitant use of anticoagulants, corticosteroids, or nonsteroidal anti-inflammatory drugs, or malignancy19. The definitions of the endpoints based on the ICD-10 codes are summarized in Table S2. Statistics Baseline characteristics are presented as mean ± standard deviation for continuous variables and frequency (percentage) for categorical variables. For the crude population, the baseline characteristics between the tegoprazan and PPI groups were compared using the independent two-sample t-test for continuous variables and the chi-square test or Fisher’s exact test for categorical variables. To mitigate confounding by indication and selection bias due to non-random treatment assignment, PS matching was performed between the tegoprazan and PPI groups. PS was calculated using multivariable logistic regression, and the included variables were sex, age, hypertension, diabetes, dyslipidemia, chronic kidney disease, congestive heart failure, prior PCI, prior stroke, Helicobacter pylori infection, GI bleeding, and malignancy or cancer. Patients in the tegoprazan group were matched with those in the PPI group in a 1:2 ratio without replacement using a caliper width of 0.1 standard deviations of the PS logit. After PS matching, covariate balance was assessed using the standardized mean difference (SMD), with an absolute SMD of less than 0.1 considered indicative of adequate balance. Group comparisons were performed using the paired t-test for continuous variables and McNemar’s test for categorical variables. The Kaplan–Meier estimator was used to estimate the cumulative incidence of outcomes over time. Subsequently, the log-rank test was used to compare the cumulative incidence curves between the two groups. Cox proportional hazards regression models were used to evaluate the association between the use of tegoprazan or PPIs and risk of the study outcomes, and the results are expressed as hazard ratio (HR) and 95% confidence interval (CI). Subgroup analyses were performed based on the type of P2Y12 inhibitor, presence of risk factors for GI bleeding, and comparisons between tegoprazan and individual PPIs. All statistical analyses were performed using SAS software (version 9.3; SAS Institute, Cary, NC, USA). Two-sided P values < 0.05 were considered statistically significant. Results Study population and baseline characteristics Of the 51,161 patients with a diagnosis of AMI who initially underwent PCI with stent implantation, 21,276 patients who were prescribed either tegoprazan or PPIs satisfied the study criteria. Among them, 2,075 (9.75%) received tegoprazan and 19,201 (90.25%) received PPIs (Fig. 1). The baseline patient characteristics are shown in Table 1. The mean age of the overall study population was 65.2 ± 12.6 years, and 75.8% were men. The patients treated with tegoprazan were younger than those treated with PPIs. A comparison of CV risk factors showed that the prevalence of a history of coronary artery bypass graft surgery was significantly higher in the tegoprazan group than in the PPI group. There was no significant difference in the risk of GI bleeding between the tegoprazan and PPI groups. The tegoprazan group had a significantly higher prescription rate for potent P2Y12 inhibitors such as ticagrelor and prasugrel compared to the PPI group. In the PPI group, clopidogrel was the predominantly prescribed antiplatelet agent. After PS matching, baseline clinical parameters and comorbid conditions were well balanced between the tegoprazan and PPI groups. A total of 4,150 patients in the PPI group were matched with 2,075 patients in the tegoprazan group, and the baseline characteristics and risk factors in the two groups were evenly matched (Figure S1). Table 1Baseline characteristics of patients treated with tegoprazan and proton-pump inhibitor before and after propensity score matching.VariablesCrude population1:2 PS-matched populationTegoprazan(n = 2,075)PPI(n = 19,201)AbsoluteSMDTegoprazan(n = 2,075)PPI(n = 4,150)AbsoluteSMDAge,years64.34 (12.9)65.25 (12.5)0.0764.34 (12.9)65.26 (12.6)0.07Age, over 65936 (45.1)9,272 (48.3)0.06936 (45.1)1,988 (47.9)0.06Sex0.030.04Male, n (%)1,593 (76.8)14,527 (75.7)1,593 (76.8)3,110 (74.9) Cardiovascular risk factors Hypertension, n (%)649 (31.3)6,228 (32.4)0.03649 (31.3)1,381 (33.3)0.04Diabetes, n (%)484 (23.3)4,405 (22.9)0.01484 (23.3)972 (23.4)< 0.01Dyslipidemia, n (%)471 (22.7)4,327 (22.5)< 0.01471 (22.7)990 (23.9)0.03Chronic kidney disease, n (%)113 (5.5)1,139 (5.9)0.02113 (5.5)249 (6.0)0.02Prior PCI, n (%)161 (7.8)1,462 (7.6)< 0.01161 (7.8)338 (8.1)0.02Prior CABG, n (%)14 (0.7)52 (0.3)0.0614 (0.7)13 (0.3)0.05Congestive heart failure, n (%)83 (4.0)723 (3.8)0.0183 (4.0)151 (3.6)0.02Peripheral arterial disease, n (%)58 (2.8)623 (3.2)0.0358 (2.8)128 (3.1)0.01Prior stroke, n (%)110 (5.3)932 (4.9)0.02110 (5.3)204 (4.9)0.02 GI bleeding risk factors Helicobacter pylori infection, n (%)13 (0.6)128 (0.7)< 0.0113 (0.6)25 (0.6)< 0.01Gastrointestinal bleeding, n (%)36 (1.7)376 (2.0)0.0236 (1.7)83 (2.0)0.02Malignancy or cancer, n (%)110 (5.3)957 (5.0)0.01110 (5.3)215 (5.2)< 0.01Steroid, n (%)42 (2.0)473 (2.5)0.0342 (2.0)98 (2.4)0.02NSAIDs, n (%)223 (10.8)2,198 (11.5)0.02223 (10.8)496 (12.0)0.04 Discharge medications Aspirin, n (%)2,061 (99.3)19,090 (99.4)0.012,061 (99.3)4,120 (99.3)< 0.01P2Y12 inhibitor, n (%)2,061 (99.3)19,120 (99.6)0.032,061 (99.3)4,130 (99.5)0.03Clopidogrel, n (%)1,052 (50.7)10,787 (56.2)0.111,052 (50.7)2,337 (56.3)0.11Ticagrelor, n (%)804 (38.8)6,723 (35.0)0.08804 (38.8)1,440 (34.7)0.08Prasugrel, n (%)205 (9.9)1,610 (8.4)0.05205 (9.9)353 (8.5)0.05ARB or ACE inhibitor, n (%)1,266 (61.0)12,008 (62.5)0.031,266 (61.0)2,611 (62.9)0.04Beta blocker, n (%)1,507 (72.6)14,174 (73.8)0.031,507 (72.6)3,053 (73.6)0.02Statin, n (%)2,032 (97.9)18,797 (97.9)< 0.012,032 (97.9)4,059 (97.8)< 0.01 PPI type Omeprazole, n (%)167 (0.9)48 (1.2)Pantoprazole or S-pantoprazole, n (%)3,073 (16.0)637 (15.4)Lansoprazole, n (%)3,729 (19.4)791 (19.1)Rabeprazole, n (%)3,683 (19.2)813 (19.6)Esomeprazole, n (%)5,657 (29.5)1,229 (29.6)Dexlansoprazole, n (%)2,397 (12.5)520 (12.5)Ilaprazole, n (%)495 (2.6)112 (2.7)Values are presented as mean (standard deviation) for continuous variables and frequency (%) for categorical variables.Abbreviations; ACE=angiotensin-converting enzyme, ARB=angiotensin II receptor blocker, CABG=coronary artery bypass grafting, GI=gastrointestinal, NSAID=nonsteroidal anti-inflammatory drug, PCI=percutaneous coronary intervention, PPI=proton pump inhibitor, SMD=standardized mean difference. Baseline characteristics of patients treated with tegoprazan and proton-pump inhibitor before and after propensity score matching. Values are presented as mean (standard deviation) for continuous variables and frequency (%) for categorical variables. Abbreviations; ACE=angiotensin-converting enzyme, ARB=angiotensin II receptor blocker, CABG=coronary artery bypass grafting, GI=gastrointestinal, NSAID=nonsteroidal anti-inflammatory drug, PCI=percutaneous coronary intervention, PPI=proton pump inhibitor, SMD=standardized mean difference. Comparison of clinical outcomes between the tegoprazan and PPI groups The primary and secondary endpoints of the crude and PS-matched populations are shown in Table 2. In the crude population, the 1-year incidence of GI bleeding, the co-primary efficacy endpoint, was significantly lower in the tegoprazan group than in the PPI group (HR 0.74, 95% CI 0.56–0.96, P = 0.03). Regarding the co-primary safety endpoint, there was no significant difference in the 1-year incidence rate of MACCEs between the two groups (HR 0.99, 95% CI 0.71–1.39, P = 0.97). In terms of the secondary endpoints, the incidence of major bleeding was significantly lower in the tegoprazan than in the PPI group (HR 0.65, 95% CI 0.48–0.90, P < 0.01). However, the incidence rates of MI, stroke, and ICH were not significantly different between the groups. In the PS-matched cohort, the tegoprazan group showed results consistent with those of the crude analysis, demonstrating a lower risk of GI (HR 0.72, 95% CI 0.54–0.98, P = 0.04) and major bleeding (HR 0.69, 95% CI 0.49–0.98, P = 0.04) at 1 year without a significant increase in the incidence of MI (HR 0.83, 95% CI 0.53–1.31, P = 0.43), stroke (HR 0.95, 95% CI 0.47–1.94, P = 0.89), or MACCEs (HR 0.86, 95% CI 0.59–1.26, P = 0.45) (Figs. 2 and 3). In the subgroup analyses stratified by the type of P2Y12 inhibitor, the tegoprazan group had a numerically lower rate of GI bleeding without an increase in the incidence of ischemic events compared to the PPI group, although none of the differences reached statistical significance (Figure S2). In both the high- and low-risk GI bleeding groups, and in comparison with individual PPIs, the incidence of GI bleeding was numerically lower in the tegoprazan group than in the PPI group (Figures S3 and S4). Table 2Primary and secondary endpoints of patients treated with tegoprazan and PPI in crude and propensity score matched population.Crude population1:2 PS-matched population N Event (%)Unadjusted HR (95% CI)p value N Event (%)HR (95% CI)p value GI bleeding Tegoprazan207557 (2.8)0.74 (0.56–0.96)0.03207557 (2.8)0.72 (0.54–0.98)0.04PPI19,201753 (3.9)reference4150166 (4.0)reference MACCE Tegoprazan207537 (1.8)0.99 (0.71–1.39)0.97207537 (1.8)0.86 (0.59–1.26)0.45PPI19,201378 (2.0)reference415095 (2.3)reference MI Tegoprazan207526 (1.3)0.99 (0.66–1.48)0.95207526 (1.3)0.83 (0.53–1.31)0.43PPI19,201271 (1.4)reference415070 (1.7)reference Stroke Tegoprazan207511 (0.5)1.01 (0.54–1.88)0.97207511 (0.5)0.95 (0.47–1.94)0.89PPI19,201107 (0.6)reference415025 (0.6)reference Major bleeding Tegoprazan207541 (2.0)0.65 (0.48–0.90)< 0.01207541 (2.0)0.69 (0.49–0.98)0.04PPI19,201615 (3.2)reference4150126 (3.0)reference ICH Tegoprazan20753 (0.1)0.47 (0.15–1.49)0.2020753 (0.1)0.63 (0.17–2.30)0.49PPI19,20163 (0.3)reference415010 (0.2)referenceValues are shown as number (percentage) unless otherwise indicated. Multivariable analyses and propensity score matching were performed using the following covariates: sex, age, hypertension, diabetes, dyslipidemia, chronic kidney disease, congestive heart failure, prior PCI, prior stroke, Helicobacter pylori infection, gastrointestinal bleeding, and malignancy or cancer.Abbreviations; CI=confidence interval, GI=gastrointestinal, HR=hazard ratio, ICH=intracranial hemorrhage, MACCE=major adverse cardiac and cerebrovascular events, MI=myocardial infarction, PPI=proton pump inhibitor, PS=propensity score. Primary and secondary endpoints of patients treated with tegoprazan and PPI in crude and propensity score matched population. Values are shown as number (percentage) unless otherwise indicated. Multivariable analyses and propensity score matching were performed using the following covariates: sex, age, hypertension, diabetes, dyslipidemia, chronic kidney disease, congestive heart failure, prior PCI, prior stroke, Helicobacter pylori infection, gastrointestinal bleeding, and malignancy or cancer. Abbreviations; CI=confidence interval, GI=gastrointestinal, HR=hazard ratio, ICH=intracranial hemorrhage, MACCE=major adverse cardiac and cerebrovascular events, MI=myocardial infarction, PPI=proton pump inhibitor, PS=propensity score. Kaplan–Meier curve for GI bleeding and MACCEs after propensity score matching. (A) GI bleeding, (B) MACCEs. Abbreviations: CI, confidence interval; GI, gastrointestinal; HR, hazard ratio; MACCEs, major adverse cardiac and cerebrovascular events; PPI, proton pump inhibitor. Kaplan–Meier curve for MI, stroke, major bleeding and intracranial hemorrhage after propensity score matching. (A) MI, (B) stroke, (C) major bleeding, and (D) intracranial hemorrhage. Abbreviations: CI, confidence interval; HR, hazard ratio; MI, myocardial infarction. Discussion This nationwide population-based cohort study found that tegoprazan use was associated with a significantly lower incidence of GI bleeding at 1 year compared with that following PPI use in patients with AMI receiving DAPT after PCI. In addition, the incidence of major bleeding was significantly lower in patients treated with tegoprazan than in those treated with PPI. However, the event rates of MACCE, MI, and stroke were not significantly different between the two groups. To the best of our knowledge, this is the first large-scale study to evaluate the effect of tegoprazan on the risk of ischemia and bleeding in patients with AMI receiving DAPT after PCI. The European guidelines recommend routine PPI co-prescription as a Class I indication for all patients on DAPT4, whereas the American guidelines limit PPI use to patients with an established high risk of GI bleeding3. However, few randomized controlled trials have directly evaluated the GI-protective effects of PPIs in patients with AMI, and most available evidence was largely derived from small-scale studies and trials exclusively targeting the AMI population8,20,21. In addition, although PPIs are widely accepted as standard gastroprotective agents in this setting, clinical data comparing PPIs with newer P-CABs remain scarce, particularly in patients with AMI who require potent P2Y12 inhibitors including ticagrelor or prasugrel. Therefore, the present study addresses these important gaps in the current evidence by showing that tegoprazan use is associated with a lower risk of bleeding complications than PPI use, without increasing the risk of ischemic events in patients with AMI receiving DAPT. Previous studies have suggested that the gastroprotective efficacy of P-CABs is comparable to that of PPIs in patients with CV diseases. In a nationwide Japanese cohort of patients with IHD receiving antithrombotic agents, vonoprazan was non-inferior to PPIs in preventing upper GI bleeding over 6 months (3.14% in the vonoprazan group vs. 4.17% in the PPI group, P for non-inferiority < 0.01)22. In a predefined subgroup analysis of patients receiving DAPT, the incidence of upper GI bleeding was 2.82% for vonoprazan and 3.96% for PPIs, with no significant difference between the two groups (adjusted HR 0.74, 95% CI 0.48–1.16, P = 0.19). More recently, a Korean nationwide cohort study of post-PCI patients receiving DAPT reported that the use of P-CABs, including tegoprazan and fexuprazan, was associated with no significant difference in the risk of upper GI bleeding compared to PPIs (adjusted HR 1.17, 95% CI 0.62–2.19, P = 0.631)23. However, the present study observed a statistically significant reduction in the risk of GI bleeding after 12 months of tegoprazan use than with PPIs in patients with AMI. This discrepancy with prior studies may be attributable to several factors. First, the previous nationwide vonoprazan study employed a 6-month non-inferiority design that was not powered to detect superiority. Second, the 12-month follow-up of the present study provided greater person-time and more events, yielding enhanced statistical power to detect a between-group difference. Third, our cohort was confined to patients with AMI undergoing PCI while receiving DAPT, frequently including potent P2Y12 inhibitors, a population at higher bleeding risk than the heterogeneous cohorts of earlier studies, in whom the gastroprotective benefit would become evident. The rapid onset, sustained acid inhibition, and minimal interaction with CYP2C19 may contribute to more consistent intragastric pH control and enhanced mucosal protection with tegoprazan use during DAPT24–26. Regarding ischemic outcomes, clinical evidence on the safety of tegoprazan in patients with AMI remains limited. Previous observational studies have suggested an increased risk of CV ischemic events when PPIs are co-administered with clopidogrel, likely because of pharmacokinetic interactions involving the CYP2C19 metabolism27–29. Certain PPIs, such as omeprazole and esomeprazole, are known CYP2C19 inhibitors and may interfere with the hepatic bioactivation of clopidogrel, potentially attenuating its antiplatelet efficacy30–32. In contrast, tegoprazan is primarily metabolized by CYP3A4 and does not inhibit CYP2C19, thereby minimizing the potential for such interactions25. Reflecting these pharmacokinetic characteristics, the incidence of MACCE, MI, and stroke did not differ significantly between the tegoprazan and PPI groups in the present study. This finding is further supported by a recent clinical pharmacodynamic study that demonstrated no significant differences in platelet reactivity unit values at 3, 6, and 12 months between patients treated with tegoprazan and those receiving PPIs, with no significant differences in the prevalence of high on-treatment platelet reactivity33. These results support the ischemic safety of tegoprazan, particularly in patients treated with clopidogrel. Our findings should be interpreted in the context of the East Asian population, which is known to exhibit a unique balance between thrombotic and bleeding risks, commonly referred to as the East Asian paradox12. Despite higher on-treatment platelet reactivity and greater prevalence of CYP2C19 loss-of-function alleles, East Asian patients tend to experience fewer ischemic events but are more susceptible to bleeding complications after PCI than are Western populations11. These characteristics emphasize the importance of identifying strategies to minimize the bleeding risk in East Asian patients. Therefore, the reduction in bleeding events observed with tegoprazan in the present study is clinically meaningful. Since tegoprazan provides potent acid suppression without CYP2C19-mediated drug interactions, it may be considered a useful alternative to conventional PPIs for GI protection in East Asian patients receiving DAPT, in whom maintaining an appropriate balance between ischemic efficacy and bleeding safety is particularly important. Conversely, in Western populations, the lower prevalence of CYP2C19 loss-of-function alleles and the more frequent use of potent P2Y12 inhibitors may attenuate the clinical relevance of the interaction between clopidogrel and PPI, and consequently the advantage offered by the absence of CYP2C19 inhibition with tegoprazan. Nevertheless, because the gastroprotective effect of tegoprazan is not ethnicity-specific, a reduction in GI bleeding could plausibly extend to Western patients, although dedicated randomized studies are needed to confirm these findings. This study has several limitations. First, its retrospective observational design and use of administrative claims data introduce the possibility of residual confounders from unmeasured factors, although we performed PS matching to balance the variables and minimize potential bias. Second, the treatment allocation was nonrandomized, and clinicians may have prescribed tegoprazan to patients with a higher risk of bleeding, introducing indication bias. However, this bias would likely favor the PPI group, although better outcomes were observed with tegoprazan. Third, the use of ICD-10 codes to define outcomes may have limited sensitivity and led to incomplete detection of minor or outpatient-managed bleeding events. As this misclassification is presumed to be non-differential between groups, the observed reduction in gastrointestinal bleeding associated with tegoprazan may be regarded as a conservative estimate of the true effect on clinically significant events. We focused on hospitalizations requiring GI bleeding and may have missed minor or outpatient-managed events. Furthermore, upper and lower GI bleeding were not distinguished. Fourth, because the HIRA claims database could not be linked to the death registry of Statistics Korea, all-cause and cardiovascular mortality could not be reliably assessed, and the composite endpoint was therefore limited to myocardial infarction and stroke. Fifth, because the HIRA database records prescription claims rather than actual medication use, neither the continuation of the study acid-suppressant drugs nor the precise duration of dual antiplatelet therapy during follow-up could be directly confirmed. Finally, the HIRA claims database lacks angiographic and procedural details including lesion location and complexity as well as stent number, diameter, length, and type, and we were therefore unable to adjust for these factors. In conclusion, this nationwide, real-world cohort study revealed that tegoprazan use was associated with a significant reduction in the incidence of GI bleeding and major bleeding at 1 year compared to PPI use among patients with AMI receiving DAPT after PCI. Moreover, there were no significant differences in the incidence of ischemic events, including MI, stroke, and MACCE, between the tegoprazan and PPI groups. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Author contributions Design of the work: LOH and KY; Data acquisition: HSJ; Data analysis: LOH, HSJ and KY; Dataset preparation: HSJ; Interpretation of the results: CSH, HSJ, RJW, LOH, IE, CDK and KY; Drafted the work: CSH, LOH and KY; Substantively revised the manuscript: all authors; All authors read and approved the final version of the manuscript. Funding This study was funded by a grant from HK inno.N Corporation (Gyeonggi-do, South Korea). No funder/sponsor had any role in the following: design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Competing interests Dr. Yongcheol Kim reports research grants from HK inno.N, Chong Kun Dang, and Jeilpharm. The remaining authors declare no conflicts of interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Oh-Hyun Lee MD and Seok-Jae Heo PhD contributed equally to this work. Contributor Information Seong Huan Choi, Email: seonghuan2@hanmail.net. Yongcheol Kim, Email: yongcheol@yuhs.ac. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.